Format

Send to

Choose Destination
Front Neuroendocrinol. 2014 Aug;35(3):370-84. doi: 10.1016/j.yfrne.2014.02.002. Epub 2014 Mar 4.

Sex differences in Parkinson's disease.

Author information

1
Division of Brain Sciences, Department of Medicine, Imperial College London, Hammersmith Campus, Du Cane Road, London W12 0NN, United Kingdom. Electronic address: g.gillies@imperial.ac.uk.
2
Division of Brain Sciences, Department of Medicine, Imperial College London, Hammersmith Campus, Du Cane Road, London W12 0NN, United Kingdom.

Abstract

Parkinson's disease (PD) displays a greater prevalence and earlier age at onset in men. This review addresses the concept that sex differences in PD are determined, largely, by biological sex differences in the NSDA system which, in turn, arise from hormonal, genetic and environmental influences. Current therapies for PD rely on dopamine replacement strategies to treat symptoms, and there is an urgent, unmet need for disease modifying agents. As a significant degree of neuroprotection against the early stages of clinical or experimental PD is seen, respectively, in human and rodent females compared with males, a better understanding of brain sex dimorphisms in the intact and injured NSDA system will shed light on mechanisms which have the potential to delay, or even halt, the progression of PD. Available evidence suggests that sex-specific, hormone-based therapeutic agents hold particular promise for developing treatments with optimal efficacy in men and women.

KEYWORDS:

Neuroprotection; Nigrostriatal dopaminergic pathways; Parkinson’s disease; Sex differences; Sex hormones

PMID:
24607323
PMCID:
PMC4096384
DOI:
10.1016/j.yfrne.2014.02.002
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center